All News
ICYMI: Allopurinol Safety in CKD Patients
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
Read Article
ICYMI: Update on Axial SpA at EULAR 2022
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
Read Article
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/NEZDB20OXN https://t.co/4123Gh2v2Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/oa619uNgnB https://t.co/gyNnsMDXGo
Links:
Dr. John Cush RheumNow ( View Tweet)
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. https://t.co/0lcYkjFj3D
Dr. John Cush RheumNow ( View Tweet)
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis
https://t.co/UisuOOABxG
#EULAR2022 https://t.co/Og8opUJO2h
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/5EKmvIwTpV https://t.co/nh2bNkSp8G
Links:
Dr. John Cush RheumNow ( View Tweet)
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush RheumNow ( View Tweet)
Adults with JIA: It ain’t all child’s play
https://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast up—“What Worries You, Masters You”
We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
https://t.co/jRaLCQAt9K https://t.co/opa22JqU41
Links:
Dr. John Cush RheumNow ( View Tweet)
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt
Dr. John Cush RheumNow ( View Tweet)
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u
Links:
Dr. John Cush RheumNow ( View Tweet)
Inferior IL-17 Inhibitor Responses in Psoriatic Women
Pooled data from two large (IXE trials show that male patients had greater clinical responses than did female patients with PsA are largely unexplored. Reasons for this is unexplained.
https://t.co/OAu6gCweDt https://t.co/lsM6hZUwNQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/7s38a67C1r https://t.co/oXLb1ctoc7
Links:
Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations
The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." A great reference to print & carry.
https://t.co/0K8LP3LA9j https://t.co/1fJlzPKLWl
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Clinical Review 15 min podcast on treatment of carpal tunnel syndrome and trigger finger and common hand problems in clinical practice; featuring Drs. Mary M. McDermott, and Kelly Currie https://t.co/IhD6iqVyqC https://t.co/aChPLIbuEu
Links:
Dr. John Cush RheumNow ( View Tweet)
The EMA's CHMP has positively recommended upadacitinib for use in Non-radiographic axial spondyloarthritis (nr-axSpA) based on Phase 3 SELECT-AXIS 2 study showing superior ASAS40 responses at week 14 https://t.co/uc7oOKglLX https://t.co/yz7M8U3rkk
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Page on "What is Carpal Tunnel Syndrome ? A great patient resource, full read with graphics https://t.co/lL9209YpdL https://t.co/28ceu2obma
Links:
Dr. John Cush RheumNow ( View Tweet)
🆕🚨Possible future avenues for myositis therapeutics: DM,IMNM&IBM
Current treatment options in IIM management
1st line:GC+
Skin➡️MTX/AZR/MMF
Muscle➡️AZR/MMF/MTX
Lung➡️AZR/MMF
Dysphagia/Diaphragmatic weakness➡️IVIG
RP-ILD➡️IVIG+CNI+CYC/RTX
Calcinosis➡️JAKi
https://t.co/G3vN055Gyq https://t.co/Qy9MULgeMs
Links:
EnvisionRheumat ERheumat ( View Tweet)
Idiopathic inflammatory myopathies, Camille Rasmussen #BJHM #MedEd #FOAMed #Medtwitter #Myopathy #rheumtwitter #MedStudentTwitter https://t.co/dsqwHIAqnX
Brown Journal of Hospital Medicine BrownJHM ( View Tweet)